SLC5A2 and type 2 diabetes mellitus: In terms of safety, no severe adverse reactions were observed in either treatment group, and the overall incidence of drug-related AEs was low, indicating that both dapagliflozin and linagliptin were well tolerated in patients with T2DM complicated by HF.[34–36] These findings are consistent with previous studies confirming the favorable safety profile of linagliptin, and they align with recent cardiovascular safety data on SGLT2 inhibitors.